---
title: "Lonza Group Ltd (LONN) Receives a Buy from Kepler Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274289625.md"
description: "Lonza Group Ltd (LONN) has received a Buy rating from Kepler Capital, with a price target of CHF670.00, according to analyst Pablo de Renteria. He has an average return of -3.5% and a 42% success rate. Additionally, Goldman Sachs analyst James Quigley also issued a Buy rating for Lonza. However, TipRanks upgraded the stock to a Hold on the same day."
datetime: "2026-01-30T10:06:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274289625.md)
  - [en](https://longbridge.com/en/news/274289625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274289625.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274289625.md) | [繁體中文](https://longbridge.com/zh-HK/news/274289625.md)


# Lonza Group Ltd (LONN) Receives a Buy from Kepler Capital

In a report released on January 28, Pablo de Renteria from Kepler Capital maintained a Buy rating on Lonza Group Ltd, with a price target of CHF670.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, de Renteria is an analyst with an average return of \-3.5% and a 42.00% success rate. de Renteria covers the Healthcare sector, focusing on stocks such as Laboratorios Farmaceuticos Rovi, Almirall, and Lonza Group Ltd.

In addition to Kepler Capital , Lonza Group Ltd also received a Buy from Goldman Sachs’s James Quigley in a report issued yesterday. However, on January 28, TipRanks – xAI upgraded Lonza Group Ltd (Six Swiss: LONN) to a Hold.

### Related Stocks

- [Lonza Group AG (LZAGY.US)](https://longbridge.com/en/quote/LZAGY.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Lonza Group AG (O6Z.SG)](https://longbridge.com/en/quote/O6Z.SG.md)

## Related News & Research

- [Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277492684.md)
- [Veeva Systems Q4 revenue eases past estimates](https://longbridge.com/en/news/277834275.md)
- [Rallybio to acquire Candid Therapeutics](https://longbridge.com/en/news/277617458.md)
- [908 Devices Q4 revenue beats on FTIR product strength](https://longbridge.com/en/news/277617498.md)
- [FDA official says UniQure fell short on Huntington's trial, defends new study request](https://longbridge.com/en/news/277874344.md)